# Safety and Efficacy Study of TRC150094 to Improve the CV Risk in Subjects With Diabetes, Dyslipidemia and Hypertension

Study · id `cardio:ct-nct03254446` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03254446](<https://clinicaltrials.gov/study/NCT03254446>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT03254446

Browse, organ or system: Blood vessels; Metabolism  
Browse, condition area: Risk and prevention; High blood pressure; Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 1250 participants.

## Technical summary

Registry record NCT03254446. Randomized; quadruple masking; primary purpose treatment. Start 2018-03-12 (actual); primary completion 2022-04 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 1250 participants (planned count; ClinicalTrials.gov record NCT03254446, source copy `cardio:ctgov-nct03254446-2020-07-17`, retrieved 2026-10-26)
- Started: 2018-03-12 (actual) (ClinicalTrials.gov record NCT03254446, source copy `cardio:ctgov-nct03254446-2020-07-17`, retrieved 2026-10-26)
- Primary completion: 2022-04 (anticipated) (ClinicalTrials.gov record NCT03254446, source copy `cardio:ctgov-nct03254446-2020-07-17`, retrieved 2026-10-26)
- Completion: 2022-08 (anticipated) (ClinicalTrials.gov record NCT03254446, source copy `cardio:ctgov-nct03254446-2020-07-17`, retrieved 2026-10-26)
- Countries: Brazil; India; Philippines (ClinicalTrials.gov record NCT03254446, source copy `cardio:ctgov-nct03254446-2020-07-17`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03254446-2020-07-17`, retrieved 2026-10-26)

## The registry's words

- Brief title: Safety and Efficacy Study of TRC150094 to Improve the CV Risk in Subjects With Diabetes, Dyslipidemia and Hypertension
- Condition: Diabetes
- Condition: Dyslipidemias
- Condition: Hypertension
- Intervention (Drug): TRC150094
- Intervention (Drug): Placebo
- Lead sponsor: Torrent Pharmaceuticals Limited
- Lead sponsor class: INDUSTRY
- Collaborator: IQVIA Pty Ltd
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Dyslipidemia (`cardio:dyslipidemia`)
- Registry condition terms include this condition: Diabetes mellitus (`core:diabetes-mellitus`)
- Registry condition terms include this condition: Hypertension (high blood pressure) (`core:hypertension`)
- Registry lists this organization as a collaborator: IQVIA Pty Ltd (`cardio:org-iqvia-pty-ltd`)

## Provenance

Content hash: 6341b1964456ad75ef73008ab76013f859c776d9accf84d3bc96a581cde685f0
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
